IrNewsService

Pfizer Inc. PFE Last Trading Session 18.60

dailymovers — Mon, 28 Dec 2009 13:54:24 +0000

Compugen Ltd. announced that it has signed a collaboration agreement with Pfizer for the predictive discovery by Compugen of therapeutic peptide product candidates for three drug targets of interest to Pfizer. The discovery process, which will be based on various Compugen discovery platforms and funded by Pfizer, is expected to take a few months, following which the predicted molecules will be synthesized and delivered to Pfizer. Following an evaluation period, Pfizer will have the right to exercise options for worldwide exclusive milestone and royalty bearing licenses to develop and commercialize the selected product candidates or further optimize them to obtain final potent, selective product candidates with favorable pharmacokinetic properties.

Last Trade: 18.60
Trade Time: Dec 24
Prev Close: 18.60
Open: N/A
Day’s Range: N/A – N/A
52wk Range: 11.62 – 18.99
Volume: 0
Avg Vol (3m): 54,571,400
Market Cap: 150.09B

About Pfizer Inc.

Pfizer Inc. engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide. Its Pharmaceutical segment offers Lipitor for elevated cholesterol levels in the blood; Norvasc for hypertension; Caduet for cardiovascular events; Chantix/Champix for smoking cessation; Lyrica for neuropathic pain; Geodon/Zeldox, a psychotropic agent; and Aricept for Alzheimer’s disease. It also provides Celebrex for arthritis pain, and inflammation and acute pain; Vfend for esophageal candidiasis and blood stream infections; Zyvox for bacterial infections; and Selzentry/Celsentri for adults infected with only CCR5-tropic HIV-1 detectable. In addition, this segment provides Viagra for erectile dysfunction; Detrol and Toviaz for overactive bladder; Camptosar for metastatic colorectal cancer; Sutent, an oral multi-kinase inhibitor; Xalatan/Xalacom for open-angle glaucoma and ocular hypertension; and Genotropin for growth disorders. The company’s Animal Health segment offers parasiticides, anti-inflammatories, antibiotics, vaccines, antiemetics, and anti-obesity agents.

Village Bank & Trust Financial Corp. VBFC Last Trading Session 2.37

dailymovers — Thu, 24 Dec 2009 20:05:34 +0000

Assemblies of God Credit Union has purchased one of three buildings Village Bank closed on Friday under a restructuring plan by the community bank.

AGCU closed Monday on the purchase of the 1776 E. Independence St. building, made for an undisclosed amount, according to a news release. The credit union plans to reopen the building in February as a full-service branch with loan and member services as well as a lobby and drive-through, according to the release. Additional details were not immediately available.

Last Trade: 2.37
Trade Time: Dec 24
Prev Close: 2.37
Open: N/A
Day’s Range: N/A – N/A
52wk Range: 2.01 – 5.98
Volume: 0
Avg Vol (3m): 2,404.62
Market Cap: 10.03M

About Village Bank & Trust Financial Corp.

Village Bank and Trust Financial Corp. is a bank holding company whose activities consist of investment in its wholly owned subsidiary, Village Bank (the Bank). The Company offers a range of banking and related financial services, including checking, savings, certificates of deposit and other depository services, and commercial, real estate and consumer loans. It is a community-oriented and locally managed financial institution focusing on providing personalized services to its customers. It conducts its operations from its main office/corporate headquarters location in Chesterfield County, and it has 15 branch offices. In October 2008, the Company acquired River City Bank.

Centrue Financial Corp. TRUE Last Trading Session 2.41

dailymovers — Thu, 24 Dec 2009 20:02:42 +0000

Centrue Financial Corp., the parent company of Centrue Bank, reported a net loss of $8.4 million in the third quarter. That brought the company’s net loss for the first nine months of 2009 to $23.6 million.

For shareholders, that amounted to a loss of $1.47 per ordinary share in the third quarter, or a cumulative loss of $4.13 per ordinary share for the nine-month period.

Last Trade: 2.41
Trade Time: Dec 24
Prev Close: 2.41
Open: N/A
Day’s Range: N/A – N/A
52wk Range: 1.00 – 7.15
Volume: 0
Avg Vol (3m): 13,756.9
Market Cap: 14.56M

About Centrue Financial Corp.

Centrue Financial Corporation, is a bank holding company that operates through its wholly owned subsidiary, Centrue Bank (the Bank). The Bank is a state-chartered bank engaged in commercial and retail banking, and offers a range of lending, depository and related financial services, including accepting deposits; commercial and industrial, consumer and real estate lending; trust and asset management services, and other banking services tailored for consumer, commercial and industrial and public or governmental customers. The Company operates through four segments: Retail, Commercial, Treasury and Wealth Management. As of December 31, 2008, the Bank had 30 offices (28 full-service bank branches and two back-room sales support non-banking facilities) located in markets extending from the far western and southern suburbs of the Chicago metropolitan area across Central and Northern Illinois down to the metropolitan St. Louis area.

Thomson S.A. TMS Last Trading Session 1.30

dailymovers — Thu, 24 Dec 2009 19:59:48 +0000

Thomson surged by 15 cents, or 12.4%, to $1.36 in the premarket session after the company’s restructuring plan is approved by the Suppliers’ committee and the Lenders’ committee. The three-month average daily volume for Thomson is 73,000 shares, according to Yahoo! Finance.

Last Trade: 1.30
Trade Time: Dec 24
Prev Close: 1.30
Open: N/A
Day’s Range: N/A – N/A
52wk Range: 0.43 – 2.15
Volume: 0
Avg Vol (3m): 69,823.1
Market Cap: 342.01M

About Thomson S.A.

Thomson SA provides a range of video (and enabling) technologies, systems, finished products and services to Media & Entertainment (M&E) industry. As of December 31, 2008, Thomson’s activities were organized into three divisions: Technicolor (formerly Services), Thomson Grass Valley (formerly Systems and as of January 1, 2009, Thomson Connect) and Technology, and two additional segments: Corporate and Other. The Technicolor division offers end-to-end management of video-related services for its customers in the M&E industries. Thomson Grass Valley division supplies hardware and software technology for the M&E industry in the areas of production, delivery, management, transmission, and access. Technology division includes activities, such as corporate research, licensing of patents and trademarks, and software and technology Solutions.

Tibco Software Inc. TIBX Last Trading Session 9.71

dailymovers — Thu, 24 Dec 2009 19:58:58 +0000

TIBCO’s fourth quarter 2009 conference call. At this time all participants are in a listen only mode. Presently we will conduct a question and answer session. You can also listen to this call via the Internet at www.TIBCO.com. Today’s call is individual recorded and will be available for playback from TIBCO Software’s website at www.TIBCO.com. In addition, rerun will be available through Premier Global Services for one month following today’s call by dialing 888-203-1112 from the United States or 719-457-0820 internationally. The confirmation code is 4047790.

Last Trade: 9.71
Trade Time: Dec 24
Prev Close: 9.708
Open: N/A
Day’s Range: N/A – N/A
52wk Range: 4.38 – 10.18
Volume: 0
Avg Vol (3m): 2,637,160
Market Cap: 1.65B

About Tibco Software Inc.

TIBCO Software Inc. (TIBCO) is a provider of infrastructure software. The Company provides a range of infrastructure software solutions that help organizations achieve the benefits of real-time business. The infrastructure software gives customers the ability to connect incompatible information technology assets in a service-oriented architecture and streamline activities through business process management. The Company also gives customers the information and intelligence tools they need to make decisions, known as The Power of Now. TIBCO offers a range of software products that can be sold individually to solve technical challenges. The services offered by the Company include professional services, maintenance and support, and training. In September 2008, the Company acquired Insightful Corporation, a provider of statistical data analysis and data mining solutions software. In August 2009, TIBCO acquired DataSynapse, Inc.

SMART Modular Technologies (WWH) Inc. SMOD Last Trading Session 6.59

dailymovers — Thu, 24 Dec 2009 19:56:16 +0000

Smart Modular Technologies gained 59 cents, or 12.2%, to $5.42 in the premarket session after the company posted a fiscal first-quarter profit of 7 cents a share, thrashing the Thomson Reuters average approximation by 2 cents. Revenue of $123.1 million was also over consensus targets. Smart Modular also offered earnings and income leadership for its fiscal second quarter that is above the Street’s view. The 50-day average daily volume for Smart Modular is 501,000.

Last Trade: 6.59
Trade Time: Dec 24
Prev Close: 6.59
Open: N/A
Day’s Range: N/A – N/A
52wk Range: 0.99 – 6.75
Volume: 0
Avg Vol (3m): 629,765
Market Cap: 408.40M

About SMART Modular Technologies (WWH) Inc.

SMART Modular Technologies (WWH), Inc. (SMART), is a designer, manufacturer and supplier of subsystems primarily to original equipment manufacturers (OEMs). The Company’s subsystem products include memory modules, solid state storage products, such as embedded flash and solid state drives (SSDs), embedded computing products, and display products, such as thin film transistor- liquid crystal display (TFT-LCD) products. SMART offers these products to customers worldwide. It also offers custom supply chain services including procurement, logistics, inventory management, temporary warehousing, kitting and packaging services. Its products and services are used for a variety of applications in the computing, networking, communications, printer, storage, defense and industrial markets worldwide. The Company operates in two business segments: the Memory, Display & Embedded Segment and the Adtron Segment.

Sycamore Networks, Inc. SCMRD Last Trading Session 20.26

dailymovers — Thu, 24 Dec 2009 19:54:56 +0000

Sycamore Networks, Inc. the “Registrant” filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Delaware Secretary of State the “Amendment” to effect the previously announced one-for-ten reverse stock split the “Reverse Stock Split” of the Registrant’s common stock, par value $0.001 the “Common Stock”, as authorized by the stockholders of the Company at the 2008 Annual Meeting of Stockholders held on January 6, 2009.

Last Trade: 20.26
Trade Time: Dec 24
Prev Close: 20.26
Open: N/A
Day’s Range: N/A – N/A
52wk Range: 1.98 – 37.40
Volume: 0
Avg Vol (3m): 97,275
Market Cap: 576.01M

About Sycamore Networks, Inc.

Sycamore Networks, Inc. (Sycamor) develops and markets intelligent bandwidth management solutions for fixed line and mobile network operators worldwide, and provides services associated with such products. The Company’s customers include domestic and international wireline and wireless network service providers, utility companies, enterprises, multiple systems operators and government entities (collectively service providers). The Company’s portfolio of optical switches, multiservice cross-connects and multiservice access platforms serve applications that extend across the network infrastructure, from multiservice access and regional backhaul to the optical core. The Company’s products enable network operators to provide and manage network capacity to support a range of converged services, such as voice, video and data. The Company’s intelligent bandwidth management products include optical switches, multiservice access platforms and associated network management software.

Radian Group Inc. RDN Last Trading Session 7.55

dailymovers — Thu, 24 Dec 2009 19:52:59 +0000

Radian Group Inc. was downgraded by Standard & Poor’s, citing insurer losses that exceeded the rating agency’s previous forecasts, according to a Reuters report.

In a statement, S&P said, “Although the macroeconomic environment is showing signs of improvement, the recession appears to have had a deeper impact on mortgage insurance companies than we expected.”

Last Trade: 7.55
Trade Time: Dec 24
Prev Close: 7.55
Open: N/A
Day’s Range: N/A – N/A
52wk Range: 0.95 – 12.48
Volume: 0
Avg Vol (3m): 4,089,370
Market Cap: 624.95M

About Radian Group Inc.

Radian Group, Inc., through its subsidiaries, provides credit-related insurance coverage and financial services. The company operates in three segments: Mortgage Insurance, Financial Guaranty, and Financial Services. The Mortgage Insurance segment offers credit protection for mortgage lenders and other financial services companies on residential mortgage assets. This segment serves mortgage originators, such as mortgage bankers, mortgage brokers, commercial banks, savings institutions, and credit unions. The Financial Guaranty segment insures and reinsures municipal bonds, structured finance transactions, and other credit-based risks, as well as provides credit protection on various asset classes through financial guarantees and credit default swaps.

Pluristem Therapeutics, Inc. PSTI Last Trading Session

dailymovers — Thu, 24 Dec 2009 19:51:16 +0000

Pluristem Therapeutics Inc. announced that it has accomplished dosing of the first of three dosage groups of patients in Europe with its placenta-derived cell therapy product, PLX-PAD, in a Phase Me dose-escalating clinical trial for the treatment of critical limb ischemia the end-stage of peripheral artery disease.

The three patients treated in this group received the lowest of the three doses in the trial. The Data Safety Monitoring Board an independent board monitoring the safety of PLX-PAD will meet in about 30 days to determine dose escalation to the next dose level to be administered in this trial.

Last Trade: 1.13
Trade Time: Dec 24
Prev Close: 1.13
Open: N/A
Day’s Range: N/A – N/A
52wk Range: 0.38 – 2.29
Volume: 0
Avg Vol (3m): 102,595
Market Cap: 20.90M

About Pluristem Therapeutics, Inc.

Pluristem Therapeutics Inc. is a bio-therapeutics company engaged in developing and intending to commercialize, cell therapy production technologies and products. The Company focuses on commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several degenerative, ischemic and autoimmune disorders. It is developing a pipeline of products, stored ready to use, that are derived from human placenta, a non-controversial, non-embryonic adult stromal cell source. The Company’s focuses in the development of product candidates for local administration for indications, such as Peripheral artery disease (PAD), Critical limb ischemia (CLI), intermittent claudication, neuropathic pain, wound healing and orthopedic injuries. The Company focuses on developing Placenta expanded cells- peripheral artery disease (PLX-PAD) cells as an allogeneic therapeutic product to treat CLI which results from PAD.

pSivida Corp. PSDV Last Trading Session 4.23

dailymovers — Thu, 24 Dec 2009 19:50:06 +0000

pSivida’s collaborative partner, Alimera Sciences, Inc. “Alimera”, filed a Form S-1/A with the Securities & Exchange Commission which reported the 24 month results of the two Phase 3 pivotal clinical trials for Iluvien in the treatment of Diabetic Macular Edema. Alimera reported that based on these results, it plans to submit a New Drug Application to the Food and Drug Administration for approval of the low dose of Iluvien in the second quarter of 2010, followed by registration filings in various European countries and Canada; that it intends to request Priority Review of the NDA from the FDA; and that if Priority Review is granted, it can expect a response to its NDA from the FDA in the fourth quarter of 2010.

Last Trade: 4.23
Trade Time: Dec 24
Prev Close: 4.23
Open: N/A
Day’s Range: N/A – N/A
52wk Range: 0.60 – 6.25
Volume: 0
Avg Vol (3m): 158,557
Market Cap: 77.38M

About pSivida Corp.

pSivida Corp., formerly pSivida Limited. develops drug delivery products that are administered by implantation, injection or insertion. Once administered, the drug is released on a controlled and level basis for months or years. The Company has developed with partners two of the only three products approved by the United States Food and Drug Administration (FDA) for the long-term, sustained release delivery of drug to treat chronic eye disease, and a third partnered product is in late-stage Phase III clinical trials. Its Phase III partnered product, which utilizes the third-generation of its Durasert technology system, delivers fluocinolone acetonide (FA) for the treatment of diabetic macular edema (DME). The Company has three technology systems: Durasert, BioSilicon and CODRUG. The Company’s lead BioSilicon product candidate, BrachySil, delivers therapeutic phosphorus-32, or P32, a radioactive form of phosphorus used to treat cancer, directly to solid tumors.